Antiplatelet vs R-tPA for Acute Mild Ischemic Stroke

Inclusion criteria

• Patient age ≥18 years;
• Study treatment can be started within 4.5h;
• Ischemic stroke confirmed by head CT or MRI;
• NIHSS score ≤ 5, and ≤ 1 NIHSS score in single item scores such as vision, language, neglect and single limb and no score in consciousness item;
• Premorbid mRS ≤ 1;
• Signed informed consent

Exclusion criteria

• Serious neurological deficits before onset ( mRS ≥ 2)；
• Obvious head injuries or strokes within 3 months；
• Subarachnoid hemorrhage;
• History of intracranial hemorrhage;
• Intracranial tumor, arteriovenous malformation or aneurysm;
• Intracranial or spinal cord surgery within 3 months;
• Arterial puncture at a noncompressible site within the previous seven days;
• Gastrointestinal or urinary tract hemorrhage within the previous 21 days;
• Major surgery within 1 month;
• Systolic pressure ≥180 mmHg or diastolic pressure ≥110 mmHg;
• Blood glucose < 50 mg/dl (2.7mmol/L);
• Heparin therapy or oral anticoagulation therapy within 48 hours;
• Platelet count of <100,000/mm3 (This does not need to be verified prior to randomization if clinical abnormality is not suspected);
• Oral warfarin is being taken and INR>1.6;
• Abnormal APTT;
• Pregnancy;
• Neurological deficit after epileptic seizures;
• Myocardial infarction within 3 months;
• Cerebral infarction with definite anticoagulation indications, such as cerebral infarction caused by cardiogenic embolism;
• Oral administration is not allowed due to dysphagia;
• allergy to study drugs;
• Other serious illness that would confound the clinical outcome at 90 days;
• Participating in other clinical trials within 3 months;
• patients not suitable for this clinical studies considered by researcher;